AST Asterias Biotherapeutics, Inc.

+0  (2%)
Previous Close 3.10
Open 3.10
Price To book 3.51
Market Cap 149.83M
Shares 47,566,000
Volume 75,971
Short Ratio 10.81
Av. Daily Volume 189,424

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 2017.
Non-small cell lung cancer (NSCLC)
Phase 1/2 six and nine-month data released January 24, 2017 from AIS-A 10 million-cell cohort. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017.
Cervical spinal cord injury
Phase 2b planned for 2018.
Acute myeloid leukemia (AML)

Latest News

  1. ETFs with exposure to Asterias Biotherapeutics, Inc. : April 17, 2017
  2. Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017
  3. Asterias Biotherapeutics posts 4Q loss
  4. Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress
  5. Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment
  6. Asterias Biotherapeutics to Report Fourth Quarter and Full Year Results on March 28, 2017
  7. BioTime Reports $56M Non-Cash Gain On Deconsolidation
  8. Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
  9. Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
  10. Asterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study
  11. Asterias Announces Successful Commencement of Operations at New GMP Manufacturing Facility for AST-OPC1
  12. The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
  13. ETFs with exposure to Asterias Biotherapeutics, Inc. : December 27, 2016
  14. Is HC2 Holdings Inc (HCHC) A Good Stock To Buy?
  15. ETFs with exposure to Asterias Biotherapeutics, Inc. : November 28, 2016
  16. Ryan Chavez Appointed Chief Financial Officer of Asterias Biotherapeutics
  17. Asterias Biotherapeutics Inc (AST) Stock Will Be A Monster Bull!
  18. Asterias Biotherapeutics Reports Third Quarter Results and Accelerating Enrollment of AST-OPC1 SCiStar Phase 1/2a Study
  19. Asterias Biotherapeutics Inc (AST) Stock Rips Higher